<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907722</url>
  </required_header>
  <id_info>
    <org_study_id>IndonesianCRC2</org_study_id>
    <nct_id>NCT03907722</nct_id>
  </id_info>
  <brief_title>The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI</brief_title>
  <official_title>The 3q25 rs2305619 Polymorphism is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesian Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesian Cardiovascular Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The
      rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was
      assessed by human PTX3 ELISA kit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enrolled 217 patients with acute STEMI undergoing primary PCI in a tertiary
      care academic cardiovascular center. The rs2305619 polymorphism was evaluated by real time
      PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit. The primary outcome
      of the study was the incidence of coronary microvascular obstruction defined as thrombolysis
      in myocardial infarction (TIMI) grade &lt;3 flow after primary PCI or TIMI grade 3 flow with
      myocardial blush grade 0 or 1. Patients were grouped based on the genotypic variants (AA, AG
      and GG). The primary outcome was compared among the three variants, as well as the PTX3
      concentration and 30-day mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">September 3, 2018</completion_date>
  <primary_completion_date type="Actual">August 2, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Incidence of microvascular obstruction</measure>
    <time_frame>Immediate after pci</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">217</enrollment>
  <condition>STEMI</condition>
  <condition>Microvascular Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Genotypic variants</arm_group_label>
    <description>AA, AG and GG genotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Long pentraxin 3</intervention_name>
    <description>Primary PCI</description>
    <arm_group_label>Genotypic variants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with STEMI symptom onset &lt;12h admitted to the ED and planned for primary PCI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute STEMI with symptom onset &lt;12 h and treated by primary PCI

        Exclusion Criteria:

          -  STEMI patients who received fibrinolytic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Surya Dharma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesian Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indonesian Cardiovascular Research Center</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>11420</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesian Cardiovascular Research Center</investigator_affiliation>
    <investigator_full_name>Surya Dharma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

